All In Biotech

Drug Trial Radar · NCT01380938

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)

RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)

Last checked: Nov 20, 2026Latest source record: Mar 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,150

Actual

Start

Dec 1, 2018

Primary completion

Nov 30, 2019

Study completion Nov 30, 2019

Sponsor

Lead sponsor
Casa Sollievo della Sofferenza IRCCSAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Casa di Cura Mater Dei; IRCCS L. Spallanzani; Ospedale Francesco Ferrari; Azienda Ospedaliero Universitaria di Sassari; Fondazione IRCCS Policlinico San Matteo di Pavia; S. Anna Hospital; Azienda Ospedaliero-Universitaria, Catania; Ospedale di Venosa; Ospedale Monsignor R. Dimiccoli, Barletta; IRCCS De Bellis, Castellana; USL Napoli 1; Ospedale San Giuseppe Moscati, Avellino; Cardarelli Hospital; Ospedale Civile Vittorio Emanuele II, Bisceglie; Azienda Ospedaliero-Universitaria Careggi; Azienda Ospedaliera V. Cervello; Ospedale Civile Spirito Santo; Ospedale di Canosa di Puglia; University of Palermo; San Camillo Hospital, Rome; Campus Bio-Medico University; Ospedale Sandro Pertini, Roma; Ospedali Riuniti di Foggia; Ospedale SS. Annunziata, Taranto; Ospedale di Mottola; Ospedale Santa Caterina Novella, Galatina; University of Florence; Valduce Hospital; University of Bari; Azienda Ospedaliera, Siracusa; Azienda Ospedaliera, Lucca
First posted
Jun 27, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

WRITE study aim at identifying the effectiveness of an innovative individualized schedule of treatment as compared to standard regimen in patients with chronic HCV genotype 2 and 3.

Conditions

  • Chronic Hepatitis

Interventions

  • Peginterferon alpha-2a + RibavirinDrug

    Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A). Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B). These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained virological Response (SVR)Time frame: 6 months after the end of treatment

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Infectious Diseases Unit

    Avellino, Italy

  • Clinical Medicine Unit "Mater Dei"

    Bari, Italy

  • Università di Bari

    Bari, Italy

  • Medicine Unit

    Barletta, Italy

  • Infectious Diseases Unit "V. Emanuele"

    Bisceglie, Italy

  • Medicine Unit

    Canosa di Puglia, Italy

  • Hepatology Unit

    Casarano, Italy

  • IRCCS "De Bellis"

    Castellana Grotte, Italy

  • Hepatology Unit

    Catania, Italy

  • Infectious Diseases Unit

    Catania, Italy

  • Gastroenterology Unit

    Como, Italy

  • Gastroenterology Unit Arcispedale "S. Anna"

    Ferrara, Italy

  • Gastroenterology Unit

    Florence, Italy

  • Internal Medicine University of Firenze

    Florence, Italy

  • Gastroenterology Unit

    Foggia, Italy

  • Infectious Diseases

    Foggia, Italy

  • Gastroenterology Unit

    Galatina, Italy

  • Infectious Diseases

    Lucca, Italy

  • Gastroenterology Unit

    Mottola, Italy

  • Gastroenterology Unit "Cardarelli"

    Naples, Italy

  • USL Napoli 1

    Naples, Italy

  • Hospital "V. Cervello"

    Palermo, Italy

  • Medical Clinic University of Palermo

    Palermo, Italy

  • Infectious Diseases Unit IRCCS "San Matteo"

    Pavia, Italy

  • Campus Biomedico University

    Roma, Italy

  • Hepatology Unit "S. Pertini"

    Roma, Italy

  • Hepatology Unit "san Camillo"

    Roma, Italy

  • Ospedale "Villa Betania"

    Roma, Italy

  • IRCCS "L. Spallanzani"

    Rome, Italy

  • IRCCS "Casa Sollievo della Sofferenza"

    San Giovanni Rotondo, Italy

  • Infectious Diseases Unit Ospedale Civile

    Sassari, Italy

  • Medicine Unit

    Sassari, Italy

  • Infectious Diseases

    Syracuse, Italy

  • SS. Annunziata

    Taranto, Italy

  • Medicine Unit

    Venosa, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.